NasdaqGS:CDXSLife Sciences
Assessing Codexis (CDXS) Valuation After Strong Earnings And New ECO Synthesis siRNA Agreement
Why Codexis Is Back on Investors’ Radar
Codexis (CDXS) has drawn fresh attention after reporting fourth quarter 2025 results, with revenue of US$38.92 million and net income of US$9.6 million, alongside new full year 2026 revenue guidance.
The company also recently signed an agreement to manufacture 50 grams of siRNA for a pharmaceutical partner using its ECO Synthesis platform, adding a commercial data point around its RNA manufacturing capabilities.
See our latest analysis for Codexis.
At a...